Drugs / JL19001 Injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07483970 | Mar 2026 → Mar 2027 expected | urinary bladder carcinoma | Jecho Biopharmaceuticals Co., Ltd. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-03-17 | Jecho Biopharmaceuticals Co., Ltd. | Regulatory Jechobio JL19001 Injection Approved for Second Indication to Advance Treatment of Advanced Tumors and Lymphoma jechobio.com ↗
Recently, JL19001 Injection, an innovative drug independently developed by Jecho (Tianjin) Biopharmaceutical Co., Ltd. (hereinafter referred to as "Jecho bio"), has been officially granted the Clinical Trial Approval Notice by the National Medical Products Administration (NMPA). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-03-17 | Jecho Biopharmaceuticals Co., Ltd. | Jechobio JL19001 Injection Approved for Second Indication to Advance Treatment of Advanced Tumors and Lymphoma jechobio.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JL19001 Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07483970 ↗ |